Lance Armstrong and Endurance Performance: What Clinicians Should Tell Patients

Why This Conversation Happens in Clinical Practice

Patients who train for endurance events, cyclists, triathletes, marathon runners, sometimes arrive asking about substances associated with elite sport. Lance Armstrong's 2013 confession to Oprah Winfrey, followed by the U.S. Anti-Doping Agency (USADA) 2012 reasoned decision, made EPO and testosterone household names. Clinicians who cannot speak to the pharmacology of these agents with specificity lose credibility in those conversations.

The Armstrong Admission in Clinical Context

Armstrong stated, in his own words during the 2013 interview: "EPO was probably the most significant. I went back and forth on the others." That statement is not gossip. It is a primary source that patients have seen. A clinician who responds with only a generic "those drugs are dangerous" fails the patient. The pharmacology is teachable, the risks are quantifiable, and the conversation is an opportunity for genuine harm reduction.

Armstrong's doping program, as detailed in the USADA Reasoned Decision (October 2012), included recombinant human erythropoietin (rHuEPO), exogenous testosterone, human growth hormone (hGH), cortisone, and autologous blood transfusions. Each agent carries a distinct risk profile. Grouping them together as simply "PEDs" is clinically imprecise.

What Patients Are Actually Asking

When a patient asks "what does Lance Armstrong take," they are typically asking one of three things: Can EPO make me a better athlete? Is testosterone safe for performance use? And would a doctor ever prescribe these? Each of those questions has a specific, evidence-based answer.

Erythropoietin: Pharmacology, Approved Uses, and Off-Label Risk

Recombinant human erythropoietin (epoetin alfa, darbepoetin alfa) stimulates erythroid progenitor cells in bone marrow via the erythropoietin receptor, raising red cell mass, hemoglobin concentration, and oxygen-carrying capacity. In trained athletes, exogenous EPO can raise VO2 max by approximately 5 to 7% over four to six weeks of administration, according to a controlled crossover study published in the Journal of Applied Physiology [1].

FDA-Approved Indications for EPO Agents

The FDA approves erythropoiesis-stimulating agents (ESAs) for three narrow indications: anemia secondary to chemotherapy in patients with non-myeloid malignancies, anemia in chronic kidney disease (CKD), and perioperative anemia reduction in selected surgical patients [2]. The FDA labeling for epoetin alfa carries a Boxed Warning stating that ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, and tumor progression or recurrence when administered to reach hemoglobin targets above 11 g/dL in CKD or above 10 g/dL in chemotherapy patients [2].

The Cardiovascular Risk at Supraphysiologic Doses

Supraphysiologic EPO in healthy athletes raises hematocrit to 50 to 55% or higher. Blood viscosity rises non-linearly with hematocrit: at a hematocrit of 55%, whole-blood viscosity approximately doubles compared with a normal value of 45% [3]. That viscosity increase, combined with exercise-induced dehydration, is the proposed mechanism behind multiple sudden deaths in European professional cyclists during the late 1980s and 1990s, a period that coincided with the widespread introduction of rHuEPO into the peloton [4].

A 2014 Cochrane systematic review of ESA use in critically ill patients found that ESAs significantly increased thromboembolic events (risk ratio 1.41, 95% CI 1.17 to 1.71) [5]. That signal comes from sick patients, not healthy athletes, but the thrombogenic mechanism is the same. In a healthy 30-year-old cyclist with a baseline hematocrit of 46%, driving that value to 54% with exogenous EPO represents a far more pronounced relative change.

Telling Patients the Dose Reality

Armstrong reportedly used EPO microdosing (small, frequent doses) specifically to avoid detection. Research on microdosing EPO published in the British Journal of Sports Medicine showed that doses as low as 6 IU/kg three times per week produced statistically significant increases in hemoglobin mass (P<0.001) within three weeks while staying below the WADA detection threshold [6]. The performance benefit is real. The cardiovascular risk accrues even at microdoses, because the thrombogenic effect depends on the cumulative rise in hematocrit, not the dose per injection.

Testosterone: Performance Use vs. Therapeutic Use

Testosterone is the second substance Armstrong publicly acknowledged using during competition. Exogenous testosterone in supraphysiologic doses increases muscle protein synthesis, reduces recovery time, and improves power output. A landmark NEJM trial by Bhasin et al. (1996, N=43) demonstrated that 600 mg/week of testosterone enanthate increased fat-free mass by 6.1 kg and leg-press strength by 38 kg over 10 weeks in healthy men without exercise, compared with 1.9 kg and 17 kg in the placebo plus exercise group [7].

Supraphysiologic vs. Therapeutic Testosterone

Therapeutic testosterone replacement therapy (TRT) targets a serum total testosterone of 400 to 700 ng/dL, consistent with the American Urological Association (AUA) 2018 guideline definition of eugonadal range [8]. Armstrong's alleged testosterone use during competition was supraphysiologic, aimed at accelerating recovery between Tour stages rather than correcting a documented deficiency. That distinction matters clinically: TRT in hypogonadal men (serum testosterone <300 ng/dL on two morning samples) has a different risk-benefit profile from testosterone doping in eugonadal athletes.

The Endocrine Society's 2018 Clinical Practice Guideline states: "We recommend against prescribing testosterone therapy to men who desire fertility in the near term, men with hematocrit >54%, and men with uncontrolled heart failure." [9]. Each of those contraindications is directly relevant when an athlete with a high-normal hematocrit from training asks about adding exogenous testosterone.

Hematologic Interaction Between EPO and Testosterone

Armstrong's program combined EPO and testosterone simultaneously, which is pharmacologically additive. Testosterone independently stimulates erythropoiesis by increasing endogenous EPO production and by direct androgenic effects on erythroid progenitors [10]. Combining exogenous EPO with supraphysiologic testosterone compounds the hematocrit elevation beyond what either agent produces alone. Clinicians should communicate this interaction explicitly to patients who are already on TRT and asking about ESAs, or vice versa.

Schedule III Classification and Prescribing Reality

Testosterone is a Schedule III controlled substance under the Controlled Substances Act. Prescribing it for performance enhancement in a eugonadal patient is not a legal medical indication in the United States. A clinician who prescribes testosterone to a patient with documented hypogonadism is practicing within the law. One who prescribes it to a healthy athlete seeking a Tour de France advantage is not.

Human Growth Hormone and Cortisone: Brief Clinical Summary

Armstrong also acknowledged hGH and cortisone use. Neither is central to the endurance-performance question, but patients may ask.

hGH in Endurance Athletes

Human growth hormone increases lipolysis and lean mass. A meta-analysis of 44 randomized controlled trials (N=303 athletes) published in Annals of Internal Medicine found that hGH administration increased lean body mass by 2.1 kg but produced no significant improvement in strength or aerobic exercise capacity [11]. Athletes who dope with hGH for endurance performance are getting a pharmacological effect with measurable side-effect risk (glucose intolerance, carpal tunnel, acromegalic features with chronic use) and minimal performance return on the specific quality that matters in cycling: aerobic power.

Corticosteroids and Therapeutic Use Exemptions

Cortisone and other corticosteroids are banned by WADA in competition but are available through Therapeutic Use Exemptions (TUEs). Armstrong's team obtained a retroactive TUE for triamcinolone in 1999, as documented in the USADA Reasoned Decision. Clinicians should know that patients in competitive sport who require corticosteroids for legitimate conditions (asthma, contact dermatitis, tendinopathy) must file a TUE with the relevant anti-doping authority before use, not after [12].

Blood Transfusions: The Third Pillar of the Armstrong Program

Autologous blood transfusions involve withdrawing an athlete's own blood weeks before a major event, storing it, then reinfusing it to raise red cell mass acutely. The physiological effect mirrors EPO: higher hemoglobin, higher oxygen delivery, higher sustainable power output. Unlike EPO, autologous transfusions leave no direct pharmacological marker in urine or serum, which is why the practice persisted in professional cycling after EPO testing improved.

USADA's 2012 Reasoned Decision described a sophisticated team-wide autologous transfusion program coordinated by team physician Michele Ferrari. That program required refrigerated storage, matched reinfusion timing to race stages, and relied on the same viscosity-and-thrombosis risk that EPO carries. The FDA regulates blood products under 21 CFR Part 606 [13]; autologous reinfusion for performance enhancement falls outside any approved indication.

What Clinicians Should Say to Patients: A Practical Framework

Patients who ask about Lance Armstrong's substances fall into roughly four groups. Each group needs a tailored response.

Group 1: The Curious Recreational Athlete

This patient has no intention of using anything banned. They want to understand what they heard in a podcast. The right response is education: explain the pharmacology of EPO and testosterone in plain language, give the specific cardiovascular risk numbers (hematocrit above 50%, thromboembolic risk ratio 1.41 from the Cochrane data), and confirm that these agents are not appropriate for recreational sport [5].

Group 2: The Competitive Masters Athlete Asking About Testosterone

This patient may genuinely have low testosterone and is conflating TRT with performance doping. Order two early-morning fasting testosterone levels. If both are below 300 ng/dL and the patient has symptoms (fatigue, low libido, reduced muscle mass), TRT is a legitimate clinical discussion. If testosterone is 420 ng/dL and the patient wants it higher "for racing," the answer is no, with an explanation of the legal and cardiovascular reasons why [9].

Group 3: The Patient Already Using Black-Market Substances

This patient needs a non-judgmental, medically precise approach. Get baseline labs: CBC with differential (looking for elevated hemoglobin and hematocrit), comprehensive metabolic panel, lipid panel, PSA if applicable, and an ECG if they report high-dose use. Counsel on the specific risks, document the conversation, and offer a path to supervised monitoring or cessation [8].

Group 4: The Patient With a Medical Indication for EPO or Testosterone

This patient has CKD anemia or documented hypogonadism. Prescribe according to FDA labeling and guideline targets. Make clear that the therapeutic window is narrow, that hemoglobin targets above 11 g/dL in CKD carry the Boxed Warning risk, and that supraphysiologic dosing is not part of the treatment plan [2].

The Anti-Doping Science Patients May Not Know

WADA's Prohibited List is updated annually. The 2024 Prohibited List classifies EPO and all ESAs under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and testosterone under S1 (Anabolic Agents), both prohibited in and out of competition for most sports [12]. The T/E ratio threshold of 4:1 has been used since the 1982 Los Angeles Olympics and remains the primary screening test for exogenous testosterone [14]. Athletes who have naturally elevated T/E ratios may undergo longitudinal profiling under WADA's Athlete Biological Passport, introduced in 2008.

Patients who compete in masters athletics, USAC-sanctioned cycling events, CrossFit competitions, or USPA powerlifting meets are subject to anti-doping rules that prohibit many agents commonly discussed in the TRT and peptide telehealth space. Clinicians who prescribe testosterone, hGH, or EPO-pathway agents to competing athletes should verify the sport's anti-doping rules before prescribing and document that verification.

Long-Term Health Outcomes in Doped Athletes: What the Data Show

The romantic narrative around Armstrong's program is that it worked. He won seven Tours. What the data show about long-term health is less flattering for the substances involved.

A 2017 retrospective cohort study of 786 former professional cyclists in France found that all-cause mortality was 40% lower than the general population, the "healthy athlete effect", but cardiovascular mortality followed an inverse-U pattern, with excess cardiovascular deaths among cyclists who raced during peak EPO-use eras (late 1980s to early 2000s) compared with pre-EPO cohorts [4]. That is an observational signal, not a controlled trial, but it is the best available long-term data on doped professional cyclists.

Supraphysiologic testosterone use, continued over years, suppresses the hypothalamic-pituitary-gonadal (HPG) axis. After cessation, hypogonadism may persist for six to 24 months, and in some users it may be permanent, requiring lifelong TRT [15]. Armstrong has spoken publicly about ongoing testosterone management post-career, though the clinical details are not available in the medical literature.

A 2020 systematic review in the Journal of Clinical Endocrinology and Metabolism covering 156 studies found that anabolic androgenic steroid (AAS) use was associated with left ventricular hypertrophy (LVH), reduced ejection fraction, and increased atherosclerotic plaque burden in former AAS users compared with age-matched non-using athletes [15]. These structural cardiac changes persisted years after cessation.

Practical Lab Monitoring for Patients Who Disclose PED Use

Patients who disclose current or prior PED use deserve a structured monitoring approach, not a lecture. The following panel is a reasonable starting point.

For EPO or blood-doping disclosures: CBC with differential (hemoglobin, hematocrit, RBC indices, reticulocyte count), serum ferritin and iron studies, coagulation panel (PT/INR, aPTT, D-dimer if recent use), echocardiogram if cardiovascular symptoms are present [3].

For testosterone or AAS disclosures: Serum total and free testosterone, LH, FSH, estradiol, SHBG, PSA (men over 40), CBC (polycythemia screen), lipid panel (AAS suppress HDL significantly), liver function tests, and echocardiogram for LVH screening in long-term users [15].

For hGH disclosures: Fasting glucose and HbA1c (hGH is diabetogenic), IGF-1 level, thyroid function, and wrist X-ray or bone-age assessment if use started before skeletal maturity [11].

Document all findings, counsel on cessation pathways, and refer to endocrinology or sports medicine for complex cases.

Patient Communication: Numbers That Land

Patients respond to specific numbers more than general warnings. When a patient asks whether EPO is worth the risk, these are the numbers to give:

A thromboembolic risk ratio of 1.41 from ESA use in controlled trial populations [5]. A hematocrit of 55% produces approximately double the blood viscosity of a normal hematocrit of 45% [3]. STEP-1 trial data are not relevant here, but the ESA Boxed Warning hemoglobin cutoff of 11 g/dL is directly relevant because it quantifies the narrow margin between therapeutic and dangerous [2]. The Bhasin 1996 data showing 6.1 kg lean mass gain with 600 mg/week testosterone enanthate [7] can be paired with the 2020 systematic review showing LVH and reduced ejection fraction in former AAS users [15] to give patients a balanced picture.

Specific numbers are more persuasive than generalities. The patient asking about EPO needs to hear "hematocrit 55%, double the blood viscosity" rather than "it thickens your blood."